RE: USA CE30 Nov 2021 11:25
Personally,i had thought that if Mologic had gained FDA pro-use,they would then have a good chance of a swift EUA for home-use,and if so,we could ride on their coat-tails with a manufacturing agreement for our Visitect.Even so,US approvals were always an added bonus,still could be.As some are beginning to realise,we don't need to be producing at full capacity to transform the revenues and SP. ANY covid revs from here on will only add to current SP levels.Last year,Finncap stated that the non-covid side of the business was "almost" supporting the SP at the time of 54p.We are now less than half that,and Colin's last purchase,also at 54p.As Oke stated earlier,we can easily generwte £10m revenue next year and more going forward.We may have over-estimated where the SP could go,based largely on the hope that DHSC contract/talks/machinery/MHRA approval could lead to huge orders,but i think we are now hugely under-estimating where this could go from here.Current mcap is easily underpinned by non-covid side of the business.Sentiment will change here very quickly and i'm positive we can recover losses and move back into the blue.